Skip to main content
. 2018 May 10;2018(5):CD012069. doi: 10.1002/14651858.CD012069.pub2

Halevy 2009.

Methods A patient report of complex visual hallucinations during methylphenidate treatment
Participants DSM‐IV‐R diagnosis of ADHD, combined type
Age: 15 years old
IQ: normal intelligence
Sex: male
Ethnicity: not stated
Country: Israel
Comorbidity: no (no past experience with drugs, smoking habit, or alcohol consumption. Normal physical and neurological examinations. Normal visual acuity. Electroencephalography (EEG) during a symptomatic state revealed no abnormalities and no evidence of epileptic activity)
Comedication: not stated
Sociodemographics: not stated
Interventions At 8 years of age:
Methylphenidate type: Ritalin
Methylphenidate dose: 10 mg daily (0.3 mg/kg)
Administration schedule: not stated
Treatment compliance: not stated
Discontinuation
Reintroduction of methylphenidate 7years later
Methylphenidate type: not stated
Methylphenidate dose: 0.15 mg/kg daily
Administration schedule: not stated
Treatment compliance: not stated
Outcomes Serious adverse events:
Hallucinations
Several days after initiation of treatment: visual hallucinations of rats, accompanied by some tactile hallucinations. Only present during the time the patient was under the influence of methylphenidate and disappeared thereafter. Discontinuation: immediate complete resolution Reintroduction of methylphenidate treatment. After 2 days: same complex visual hallucinations. Discontinuation: immediate complete resolution
Notes Funding/vested interest: the authors have no conflicts of interest to disclose with regard to this article
Key conclusions of the study authors: the occurrence of hallucinations after a very low dose of methylphenidate on 2 occasions may suggest an idiosyncratic reaction. The phenomenon might also be explained by a drug‐induced dysfunction of the monoamine transmitters
Comments from the study authors: given the wide use of methylphenidate, clinicians should be aware of this possible side effect
Supplemental information regarding IQ and diagnostic criteria received through personal email correspondence with the authors in August 2013 (Halevy 2013 [pers comm])